Gene expression profiling of newly diagnosed multiple myeloma patients included in the HOVON95 clinical trial

This gene expression set contains data from patients included in the HOVON95 clinical trial. Using this data the relation between a signature identifying patients with aggressive biology and clinical parameters was studied in newly diagnosed multiple myeloma patients. This dataset was used to identify the relationship between a signature for aggressive disease and clinical parameters. 240 samples were analysed, which were taken from 240 individual patients. Samples were derived from bone marrow aspirates, which were subjected to enrichment of MM cells using CD138 specific beads. RNA sample workup was performed according to the instructions for use of the MMprofilers at the SkylineDx reference lab (SkylineDx, Rotterdam, The Netherlands). Samples were hybridized to Affymetrix HG-U133 plus2 chips, using Affymetrix Inc. (Santa Clara, CA) GPR reagent for samples obtained in 2014 or earlier, and Affymetrix 3' IVT PLUS reagents for samples obtained after 2014. All samples passed wet lab and data QC acceptance criteria. Gene expressions were MAS5.0 normalized (values below 30 were truncated) with a target value of 1500. The MMprofiler CE IVD assay was used to obtain SKY92 scores, classifying a patient as high risk or standard risk.